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Summary: A simple and rapid method for the quantitative determination of antipyrine, using gas-liquid-chromato-
graphy with nitrogen detection, is described. Only one extraction step is needed, the recovery is 91.2% and the
precision varies between 3.14-1.96%. The lower limit of quantitative assay reached 0.1 mg/1 plasma. During routine
handling the method was easy, quick and cheap.
Eine einfache und empfindliche Methode für die Bestimmung von Phenazon (Antipyrin®)
mittels Gas-Chromatographie mit Stickstoffdetektor
Zusammenfassung: Eine einfache und schnelle Bestimmungsmethode für Antipyrin im Plasma mittels der Gas-Chroma-
tographie mit Stickstoffdetektor wird beschrieben. Eine einmalige Extraktion ist ausreichend, die Wiederfindungs-
rate beträgt 91,2%, die Genauigkeit variert zwischen 3,14 und l ,96%. Die Nachweisgrenze liegt bei 0,1 mg/1 Plasma.
Im Rahmen von Routinebestimmungen hat sich die Methode als spezifisch, zeitsparend und billig erwiesen.
Introduction
Since its synthesis in 1884 antipyrine has been used as
an antipyretic and later as an analgesic. From the 1930's
it went out of favour as newer analgesics became avail-
able. Subsequently antipyrine has proved to be of con-
siderable value as ä research tool in pharmacokinetic
studies (1),
Brodie &Axelrod (2) described the metabolism of anti-
pyrine and provided much of the evidence on which
the antipyrine half-life test as we know it, is based.
Antipyrine® (phenazone; l,2-dihydro-l,5-dimethyl-2-
phenyl-3H-pyrazol-3-one) is a weak base of pKa = 1.4
which after administration is rapidly absorbed and
distributed throughout total body water, with an ab*
sorption and distribution normally complete within two
hours.
Several methods for the determination of antipyrine in
plasma have been published (3-12). The disadvantage
of most of these methods is that they are time con-
suming, expensive and of low sensitivity. The method
to be described needs small sample volumes, one extrac-
tion step and, using a nitrogen detector, it is sensitive
and specific.
Materials and Methods
Apparatus
The gas chromatograms were obtained with a Perkin Elmer
3920 Model Gas Chromatograph equipped with a Thermionic
NPD Detector and a Model 56 Potentiometric Recorder (Perkin
Elmer Co., Norwalk, Connecticut 06856); the glass column
(1.2 m length and 2 mm inside diameter) was filled with 3%
Carbowax 20 M on Chromosorb WAW 100/120 mesh (W. Günt-
her Analysentechnik, D-6103 Griesheim).
Peaks were evaluated with an Autolab System I Computin
Integrator (Spectra Physics, Santa Clara, Calif. 95051). The
extractions were performed with a Model SM shaker (E. Bühler,
D-7400 Tübingen).
Reagents
All reagents were of analytical grade. Antipyrine and isopropyi-
antipyrine (for internal standard) were a gift from Hoechst AG
(D-6230 Frankfurt).
ftqcedure
Plasma samples were obtained as described (13). 1 ml plasma
was pipetted into a 25 ml glass centrifuge tube, 25 mg/1 of the
internal standard was added, the solution was alkalinized with
200 5 mpl/1 sodium hydroxide, and after addition of 6 ml
dichlormethane the tube was stoppered and shaken for 15 min;
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the tubes were centrifuged (2500 U/min) for 10 min and the
aqueous layer was aspirated and discarded; the organic phase
was transferred to a clean centrifuge tube and the solvent was
evaporated in a water bath at 40 °C under a nitrogen stream. The
residue was three times dissolved in 200 μΐ dichlormethane
and transferred to 1 ml conic vials and the contents were
evaporated under a nitrogen stream. The residue was dissolved
by vortexing 15s with 50 μΐ acetone, and 1 μΐ of this solution
was injected into the gas Chromatograph with a Hamilton
701 N microsyringe. The Chromatographie conditions were as
follows: Helium 30 ml/min; hydrogen 3 ml/min; air 120 ml/min;
detector voltage setting 3, and glass bead heating setting at 510;
the detector temperature was held at 245 °C, the glass injector
liner at 235 °C, and the column at 220 °C; the detector amplifier
was used at a setting of range 10 and attenuation 32.
Every day a calibration was made, using plasma at zero time
which was spiked with known amounts of antipyrine (5,10,
25 mg/1) and 25 mg/1 internal standard. Concentrations were
determined by using the peak area ratio of antipyrine to internal
standard, and calculating the regression line (least squares
method).
Results
Under the specific conditions in the gas Chromatograph
(fig. 1) antipyrine had a retention time of 7.10 minutes
compared to 4.17 for the standard (isopropylantipyrine).
In almost all chromatograms of human plasma a peak
preceeding antipyrine was found to have the same reten-
tion time as caffeine (5.43 min). This peak did not
interfere with the two other ones. A typical standard
curve obtained with 5-10-25 mg/1 antipyrine is shown
in figure 2, with a linear regression line. The precision
of the determination of antipyrine is presented in
table 1. For three concentrations (5,10, 25 mg/1) in
five determinations the coefficient of variation was
1.96 to 3.14%. The recovery was estimated by adding
known amounts of antipyrine and internal standard
(20 mg/1) each to 1.0 ml plasma. 91.2 ± 2.1% (n = 5) of
the added compounds could be accounted for.
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Fig. 1. Gas-liquid-chromatogram from a volunteer plasma by
the reported method. The peaks are identified by the
retention times:
t = 4.17 min = isopropylantipyrine (internal standard)
t = 5.43 min = caffeine
t = 7.10 min = antipyrine
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Fig. 2. Typical standard curve obtained with 25 mg/1 of internal
standard.
Tab. 1. Gas liquid-chromatographic estimation of antipyrine in
human plasma. 15 consecutive analyses with the calcula-
tion of the mean, standard deviation and the coefficient
of variation (CV).
Antipyrine
added
(mg/1)
5
10
25
found (χ ± s)
(mg/1)
5,09 ± 0.16
9.88 ± 0.26
25.06 ± 0.49
CV
(%)
3.14
2.63
1.96
Tab. 2. Plasma concentrations of antipyrine iti 10 healthy
volunteers 1—13 hours after an oral dose of 15 mg/kg
body weight.
Time
(h)
1
2
5
7
9
11
13
Antipyrine
X
(mg/1)
22.8
20.5
18.4
15.5
14.1
12.2
10.7
s
(mg/1)
±5.2
±4.1
±3.2
±3.1
±3.3
±3.0
±3.1
range
(mg/1)
12.9-32.7
14.7-26.2
13.5-23.4
11.0-19.4
9.8-18.6
8.2-16.4
7.0-14.4
After the oral application of 15 mg/kg antipyrine to
10 healthy volunteers, antipyrine plasma levels were
measured between one and thirteen hours. The maxi-
mum concentration was 32.7 mg/1, the minimum was
7.0 mg/1 (tab. 2).
Blank plasma samples showed no peaks in the region of
antipyrine and internal standard.
Discussion
The extraction of antipyrine from plasma described by
Lindgren et al. 197Λ (9), Huffmann et al. 1974 (8) and
Eichelbaum & Spahnbrucker 1977 (7) gave, in our
hands, inconsistent results, partly caused by the forma-
tion of emulsions. The use of dichloromethane as
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solvent avoided emulsions and gave an extraction yield
of 91.2%. The use of a nitrogen-sensitive detector
practically eliminated the solvent peak, gave a straight
base line and permitted a better peak integration, thus
making the method more specific and sensitive.
As no peak in the blank plasma interfered with the
antipyrine or internal standard, the one extraction step
was sufficient. The peak with the same retention time
as caffeine did not disturb the measurements. Most
plasma concentration levels of antipyrine were in the
range between 1 and 25 mg/1, but the presented tech-
nique could also be applied to samples that contain
0.1 mg/1, simply by increasing the amplifier sensitivity.
In relation to other methods of antipyrine determination,
which showed a recovery between 73.2% (Brinkmann
& Hengstmann (4)) and 93.5%(Lindgren et al. (9)) our
recovery of 91.2% was good. Also the coefficient of
variation of the tested concentration was within the
values of 3.9 to 7.9% found by Lindgren et al. (9) with
their gas Chromatographie method.
For us the practicability of the method was verified by
the determination of the antipyrine half-life in ten
healthy volunteers (13). In routine use, the method
was simple, rapid and cheap.
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Note added to the revised manuscript:
Drugs tested for interference
There was no interference in the antipyrine assay in
patients taking following medications:
azlocillin
cimetidine
clemastine
clonidine
diethylcarbamazine
digoxin
dipyrone
hydrochlorothiazide
penicillin G
phenylbutazone
quinidine
sulfinpyrazone
spironolactone
theophylline
triamterene
The following substances were extracted and did not
interfere:
aminophylline
ampicillin
atropine
caffeine
cefazolin
diazepam
diphenylhydramine
dihydralazine
glyburide
ergotamine
furpsemide
gentamicine
heptabarbital
lidocaine
methaqualone
metropolol
mezlocillin
neostigmine bromide
pindolol
propanolol
pentazocine
phenobarbital
promethazine
salicylic acid
theobromine
tobramycine
warfarin
References
1. Stevenson, I. H. (1977), Brit. J. Clin. Pharmacol. 4, 261-
265.
2. Brodie, B. B. & Axelrod, J. (1950), J. Pharmacol. Exp.
Therap. P5, 97-104.
3. Van Boxtei, C. J., Wilson, J. T., Lindgren, S. & Sjöqvist, F.
(1976), Europ. J. Clin. Pharmacol. P, 327-332.
4. Brinkmann, H. J. & Hengstmann, J. H. (1976), Arzneimittel-
forsch, (Drug Res.) 26, 483-484.
5. Brodie, B. B., Axelrod, J., Soberman, R. & Levy, B. B.
(1949), JfBiol. Chem. 179, 25-30.
6. Chang, R. L., Wood, A. W., Dixon, W. R., Conney, A. H.,
Anderson, K. E., Eitermann, A. J. & Alvares A. P. (1976),
Clin. Pharmacol. Therap. 20, 216-219.
7. Eichelbaum, M. & Spannbrucker, H. (1977), J. Chromat.
140, 288-292.
8. Hufman, D. H., Shoeman, D. W. & Azarnoff, D. L. (1974),
Biochem. Pharmacol. 23,197-201.
9. Lindgren, S., Collste, P., Norlander, B. & Sjöqvist, F. (1974),
Europ. J. Clin. Pharmacol. 7, 381-385.
10. Meffin, P. J., Williams, R. L. Blaschke, T. F. & Rowland,
M. (1977), J. Pharm. Sei. 66, 135-137.
11. Prescott, L. F., Adjepaon-Yamoah, K. K. & Roberts, E.
(1973), J. Pharm. Pharmacol. 25, 205-207.
12. Vesell, E. S., Passananti, G. T., Glenwright, P. A. &
Dvorchick, B. H. (1975), Clin. Pharmacol. Therap. 18,
259-272.
13. Walter, E., Staiger, Ch., de Vries, J. & Weber, E. (1980),
Prepared for publication.
Dr. Christoph Staiger
Abteilung für Klinische Pharmakologie
Medizinische Universitätsklinik
Bergheimer straße 58
D-6900 Heidelberg
J. Clin. Chem. Clin. Biochem. / Vol. 18,1980 / No. 11

